Australian-based Biota Pharmaceuticals Inc said a US agency has terminated funding for the development of its influenza drug.
The company said the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services and in charge of developing countermeasures against public health emergencies, did not provide a reason for the withdrawal of support.
